ArticleScientific reports2018
Analysis of the Genome and Metabolome of Marine Myxobacteria Reveals High Potential for Biosynthesis of Novel Specialized Metabolites.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 55 citations in OpenAlex.
- Phylogenomic analysis and characterization of a novel metagenome-assembled genome from the Bay of Bengal and description of Candidatus Niobacter visakhapatnamensis gen. nov., sp. nov.Archives of microbiology · 2026Article
- Genomic and Metabolic Features of theFoods (Basel, Switzerland) · 2026Article
- Anticancer Compounds from Myxobacteria: Current Scenario and Future Perspectives.Anti-cancer agents in medicinal chemistry · 2026Review
- A geranylgeranyl reductase homolog required for cholesterol production in Myxococcota.Journal of bacteriology · 2025Article
- MyxoPortal: a database of myxobacterial genomic features.Database : the journal of biological databases and curation · 2024Article
- Succession of microbial community composition and secondary metabolism during marine biofilm development.ISME communications · 2024Article
- Biosynthetic gene cluster synteny: Orthologous polyketide synthases in Hypogymnia physodes, Hypogymnia tubulosa, and Parmelia sulcata.MicrobiologyOpen · 2023Article
- De novo cholesterol biosynthesis in bacteria.Nature communications · 2023Article
- Biosynthetic Potential ofJournal of fungi (Basel, Switzerland) · 2023Article
- New algorithms for accurate and efficient de novo genome assembly from long DNA sequencing reads.Life science alliance · 2023Article
- Heterologous Biosynthesis of Myxobacterial Antibiotic Miuraenamide A.Molecules (Basel, Switzerland) · 2023Article
- In Silico and In Vitro Analyses Reveal Promising Antimicrobial Peptides from Myxobacteria.Probiotics and antimicrobial proteins · 2023Article
- Genomic Analysis of the Rare Slightly Halophilic Myxobacterium "Microorganisms · 2023Article
- Comparative genomics and transcriptomics insight into myxobacterial metabolism potentials and multiple predatory strategies.Frontiers in microbiology · 2023Article
- A Metabolomics-Based Toolbox to Assess and Compare the Metabolic Potential of Unexplored, Difficult-to-Grow Bacteria.Marine drugs · 2022Article
- Article
- New Deoxyenhygrolides fromMarine drugs · 2022Article
- Article
- Metagenomics UnveilsmSystems · 2021Article
- Myxobacterial Genomics and Post-Genomics: A Review of Genome Biology, Genome Sequences and Related 'Omics Studies.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comparative genomic/metabolomic analysis is a powerful tool to disclose the potential of microbes for the biosynthesis of novel specialized metabolites. In the group of marine myxobacteria only a limited number of isolated species and sequenced genomes is so far available. However, the few compounds isolated thereof so far show interesting bioactivities and even novel chemical scaffolds; thereby indicating a huge potential for natural product discovery. In this study, all marine myxobacteria with accessible genome data (n = 5), including Haliangium ochraceum DSM 14365, Plesiocystis pacifica DSM 14875, Enhygromyxa salina DSM 15201 and the two newly sequenced species Enhygromyxa salina SWB005 and SWB007, were analyzed. All of these accessible genomes are large (~10 Mb), with a relatively small core genome and many unique coding sequences in each strain. Genome analysis revealed a high variety of biosynthetic gene clusters (BGCs) between the strains and several resistance models and essential core genes indicated the potential to biosynthesize antimicrobial molecules. Polyketides (PKs) and terpenes represented the majority of predicted specialized metabolite BGCs and contributed to the highest share between the strains. BGCs coding for non-ribosomal peptides (NRPs), PK/NRP hybrids and ribosomally synthesized and post-translationally modified peptides (RiPPs) were mostly strain specific. These results were in line with the metabolomic analysis, which revealed a high diversity of the chemical features between the strains. Only 6-11% of the metabolome was shared between all the investigated strains, which correlates to the small core genome of these bacteria (13-16% of each genome). In addition, the compound enhygrolide A, known from E. salina SWB005, was detected for the first time and structurally elucidated from Enhygromyxa salina SWB006. The here acquired data corroborate that these microorganisms represent a most promising source for the detection of novel specialized metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.